DNA methylation and demethylating drugs in myelodysplastic syndromes and secondary leukemias
BACKGROUND AND OBJECTIVES: Methylation of DNA is a common epigenetic
modification that plays an important role in the control of gene expression in mammalian …
modification that plays an important role in the control of gene expression in mammalian …
Comparison of first‐line chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for people with early unfavourable or advanced stage …
N Skoetz, A Will, I Monsef, C Brillant… - Cochrane Database …, 2017 - cochranelibrary.com
Background There are two different international standards for the treatment of early
unfavourable and advanced stage Hodgkin lymphoma (HL): chemotherapy with escalated …
unfavourable and advanced stage Hodgkin lymphoma (HL): chemotherapy with escalated …
Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive …
N Schmitz, B Pfistner, M Sextro, M Sieber, AM Carella… - The Lancet, 2002 - thelancet.com
Background High-dose chemotherapy followed by transplantation of autologous
haemopoietic stem cells (BEAMHSCT) is frequently used to treat patients with relapsed …
haemopoietic stem cells (BEAMHSCT) is frequently used to treat patients with relapsed …
Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease
V Diehl, J Franklin, M Pfreundschuh… - … England Journal of …, 2003 - Mass Medical Soc
Background Faced with unsatisfactory results of treatment for advanced Hodgkin's disease,
we investigated three combinations of chemotherapy. Methods From 1993 to 1998, 1201 …
we investigated three combinations of chemotherapy. Methods From 1993 to 1998, 1201 …
Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study
A Engert, V Diehl, J Franklin, A Lohri… - Journal of Clinical …, 2009 - ascopubs.org
Purpose The HD9 trial of the German Hodgkin Study Group compared two different doses
(baseline and escalated) of the bleomycin, etoposide, doxorubicin, cyclophosphamide …
(baseline and escalated) of the bleomycin, etoposide, doxorubicin, cyclophosphamide …
ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin's lymphoma: results from the HD2000 Gruppo Italiano …
M Federico, S Luminari, E Iannitto… - Journal of Clinical …, 2009 - ascopubs.org
Purpose To compare doxorubicin, bleomycin, vinblastine, dacarbazine (ABVD) versus
bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and …
bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and …
New prognostic score based on treatment outcome of patients with relapsed Hodgkin's lymphoma registered in the database of the German Hodgkin's lymphoma …
A Josting, J Franklin, M May, P Koch… - Journal of Clinical …, 2002 - ascopubs.org
PURPOSE: To evaluate salvage treatment outcome of patients with relapsed Hodgkin's
disease (HD) and to distinguish different risk groups using identified prognostic factors …
disease (HD) and to distinguish different risk groups using identified prognostic factors …
[HTML][HTML] Involved-field radiotherapy for advanced Hodgkin's lymphoma
BMP Aleman, JMM Raemaekers, U Tirelli… - … England Journal of …, 2003 - Mass Medical Soc
Background The use of involved-field radiotherapy after chemotherapy for advanced
Hodgkin's lymphoma is controversial. Methods We randomly assigned patients with …
Hodgkin's lymphoma is controversial. Methods We randomly assigned patients with …
Stanford V and radiotherapy for locally extensive and advanced Hodgkin's disease: mature results of a prospective clinical trial
SJ Horning, RT Hoppe, S Breslin, NL Bartlett… - Journal of Clinical …, 2002 - ascopubs.org
PURPOSE: To provide more mature data on the efficacy and complications of a brief, dose-
intense chemotherapy regimen plus radiation therapy (RT) to bulky disease sites for locally …
intense chemotherapy regimen plus radiation therapy (RT) to bulky disease sites for locally …
[HTML][HTML] Time-intensified dexamethasone/cisplatin/cytarabine: an effective salvage therapy with low toxicity in patients with relapsed and refractory Hodgkin's disease
A Josting, C Rudolph, M Reiser, M Mapara, M Sieber… - Annals of …, 2002 - Elsevier
Background An important variable affecting outcome in relapsed and refractory Hodgkin's
disease (HD) is the potential of conventional salvage chemotherapy to reduce tumor volume …
disease (HD) is the potential of conventional salvage chemotherapy to reduce tumor volume …